Paper Details

  1. Home
  2. Paper Details

Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.

Author: AzzoliC G, Dagogo-JackI, GainorJ F, KennedyE, KuberskiH, LennesI, LinJ J, MuzikanskyA, SequistL V, ShawA T, StoberL L, WanatA C

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Alectinib, a drug for advanced lung cancer, is effective but resistance develops. This study investigated the safety and effectiveness of combining alectinib with bevacizumab, an antibody, to potentially delay resistance.
Paper Details　
Original Abstract of the Article :
Alectinib, a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is highly effective in advanced ALK-rearranged non-small-cell lung cancer and represents a standard first-line therapy. New strategies are needed, however, to delay resistance. We conducted a phase I/II ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666648/

データ提供：米国国立医学図書館（NLM）

Combating Resistance in ALK-Rearranged Lung Cancer: Alectinib Plus Bevacizumab

The fight against cancer is a constant battle, with researchers relentlessly seeking new strategies to outsmart the disease. This study explores the potential of combining two promising cancer therapies, alectinib and bevacizumab, to improve the treatment of advanced ALK-rearranged non-small-cell lung cancer. Alectinib, a targeted therapy that inhibits the ALK protein, has shown significant effectiveness in this type of cancer, but resistance to this treatment can develop over time. The study delves into the potential of adding bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor, to alectinib treatment.

Expanding Treatment Options for ALK-Rearranged Lung Cancer

The study's results, like the discovery of a new spring in the desert, provide evidence for the potential of combining alectinib and bevacizumab as a safe and effective strategy for treating advanced ALK-rearranged lung cancer. This combination therapy could potentially delay or prevent the development of resistance to alectinib, extending the benefits of targeted treatment for patients.

Hope on the Horizon for Lung Cancer Patients

This research, like a beacon of hope in a vast desert, offers a potential new approach to treating ALK-rearranged lung cancer. By addressing the challenge of resistance to targeted therapies, this combination approach could improve treatment outcomes and extend the lives of patients. It is a testament to the ongoing efforts of researchers to find better treatments and improve the lives of those battling cancer.

Dr.Camel's Conclusion

The fight against cancer is an ongoing journey, and this study, like a camel caravan seeking a new oasis, represents a promising step forward. The combination of alectinib and bevacizumab could be a valuable addition to the arsenal of treatments for ALK-rearranged lung cancer. It's a reminder that even in the face of adversity, there is often hope on the horizon for those seeking a cure.

Date :
  1. Date Completed 2022-03-24
  2. Date Revised 2022-10-03
Further Info :

Pubmed ID

34896762

DOI: Digital Object Identifier

PMC8666648

Related Literature

Article Analysis
・Effects of ceritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.